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Abstract: Anaerobes comprise most of the endogenous oropharyngeal microflora, and can cause infections of
airways in lung cancer patients who are at high risk for respiratory tract infections. The aim of this study was to
determine the frequency and species diversity of anaerobes in specimens from the lower airways of lung cancer
patients. Sensitivity of the isolates to conventional antimicrobial agents used in anaerobe therapy was assessed.
Respiratory secretions obtained by bronchoscopy from 30 lung cancer patients were cultured onto Wilkins-
-Chalgren agar in anaerobic conditions at 37°C for 72–96 hours. The isolates were identified using microtest Api
20A. The minimal inhibitory concentrations for penicillin G, amoxicillin/clavulanate, piperacillin/tazobactam,
cefoxitin, imipenem, clindamycin, and metronidazole were determined by E-test. A total of 47 isolates of anaer-
obic bacteria were detected in 22 (73.3%) specimens. More than one species of anaerobe was found in 16
(53.3%) samples. The most frequently isolated were Actinomyces spp. and Peptostreptococcus spp., followed by
Eubacterium lentum, Veillonella parvula, Prevotella spp., Bacteroides spp., Lactobacillus jensenii. Among anti-
biotics used in the study amoxicillin/clavulanate and imipenem were the most active in vitro (0% and 2% resis-
tant strains, respectively). The highest resistance rate was found for penicillin G and metronidazole (36% and
38% resistant strains, respectively). The results obtained confirm the need to conduct analyses of anaerobic
microflora colonizing the lower respiratory tract in patients with lung cancer to monitor potential etiologic
factors of airways infections, as well as to propose efficient, empirical therapy. (Folia Histochemica et Cytobio-
logica 2011; Vol. 49, No. 2, pp. 263–266)
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Introduction
Anaerobes are the predominant components of the
normal commensal oropharyngeal flora. In this part
of the human body, they are present in amounts be-
tween 103–109/ml and outnumber aerobic and facul-
tative microorganisms by 10:1. Anaerobic bacteria
play a significant role in the prevention of oropha-
ryngeal colonization by pathogens because some of
them can interfere with the growth of potential patho-
gens on the competitive mechanism. However, un-
der predisposing conditions such as smoking, alcohol
abuse, bad oral hygiene, prolonged hospitalization,
immunosuppression, chronic lung diseases, cancer,
and cough reflex disorders in the early post-opera-
tive period, anaerobes can cause endogenous infec-
tions of the respiratory tract including bronchitis, lung
abscess, thoracic empyema or necrotic lung inflam-
mation. Furthermore, antibiotic-related selection
pressure on the oropharyngeal flora is another known
risk factor for anaerobic respiratory tract infections.
Additionally, these organisms also present a signifi-
cant role in escalating chronic obstructive pulmonary
disease (COPD). The most frequent way of spread-
ing these infections is the aspiration of oropharyn-
geal secretions in connection with defects in the clear-
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ance mechanisms of the respiratory tract. Although
healthy adults can also experience the aspiration of
oropharyngeal secretions, e.g. during sleep, due to
efficient clearance mechanisms their lower respira-
tory tract is fortunately usually sterile [1–5].
Lung cancer patients are at high risk for respira-
tory tract infections because cancer therapy regi-
mens, as well as the underlying disease, cause both
transient neutropenia and disruption of the physio-
logical barriers in airways. Although these infections
are usually caused by aerobic or facultative bacte-
ria, anaerobes comprising most of the endogenous
oropharyngeal microbial flora can also cause infec-
tions of airways [6].
The objective of the present study was to deter-
mine the frequency as well as species diversity of
anaerobes in the lower respiratory tract specimens of
lung cancer patients. We assessed the sensitivity of
isolated anaerobic bacteria strains to conventional
antimicrobial agents used in the therapy of diseases
caused by anaerobes.
Material and methods
Patients. A total of 30 patients suffering from lung cancer
(29 men and 1 woman, mean age 46 years) were enrolled in
the present study. Patients were qualified for the study af-
ter histopathological diagnosis. Histological type of lung
cancer was determined before surgery on the grounds of
examination of specimens obtained during bronchoscopy,
sputum cytology, thin needle biopsy, supraclavicular lymph
nodes biopsy and mediastinoscopy. In this group, 27 patients
suffered from non-small cell lung cancer (NSCLC) and three
from small cell lung cancer (SCLC). Among histological
types of NSCLC of studied patients, squamos cell carcino-
ma predominated (50% of the patients), followed by large
cell carcinoma, adenocarcinoma and mixed carcinoma.
During the previous month, all patients qualified for the
study had not: suffered from airways infections, taken anti-
microbial agents, taken immunological system-influencing
drugs, received a blood transfusion, or suffered from an al-
lergic disease. The study was approved by the Ethical Com-
mittee of the Medical University of Lublin. Informed con-
sent was obtained from all patients.
Microbiological assay. Respiratory secretions obtained by
fiberoscopic bronchoscopy using a protected specimen brush
(PSB) catheter from 30 lung cancer patients were cultured
onto Wilkins-Chalgren Agar (Biocorp, Poland) with vanco-
mycin and nalidixic acid and Wilkins-Chalgren Agar with
colistin and nalidixic acid for selective isolation of Gram-
-negative and Gram-positive anaerobes, respectively. Plates
were incubated in anaerobic conditions at 37oC for 72–96
hours. The isolates were identified using microtest Api 20A
(BioMerieux). The minimal inhibitory concentrations
(MICs) for penicillin G, amoxicillin/clavulanate, piperacil-
lin/tazobactam, cefoxitin, imipenem, clindamycin, and met-
ronidazole were determined by E-test (AB BIODISK) ac-
cording to Clinical Laboratory Standard Institute (CLSI)
recommendations. With each susceptibility test run, quality
control was performed with Bacteroides fragilis ATCC
25285. Beta-lactamase production was detected using a ni-
trocephin test (Becton Dickinson).
Results
A total of 47 isolates of anaerobic bacteria were de-
tected in the respiratory secretions of 22/30 (73.3%)
lung cancer patients. The number of anaerobic spe-
cies in a single specimen varied from one to four. More
than one species of anaerobe was found in 16/30
(53.3%) samples: four, three and two different spe-
cies of bacteria were identified in 2/30 (7%), 5/30
(17%) and 9/30 (30%) patients, respectively. The spe-
cies of anaerobes colonizing the lower respiratory tract
are listed in Table 1. Generally, from the examined
samples, isolates of Gram-positive bacteria were cul-
tured more frequently than those of Gram-negative
bacteria, comprising 78.7% of all the isolates. Among
Gram-positive anaerobes, the commonest was Acti-
nomyces spp. (15 strains) and Peptostreptococcus spp.
(14 strains), followed by Eubacterium lentum (seven
strains); Veillonella parvula (six strains) was the com-
monest Gram-negative anaerobic bacteria.
The anaerobic bacteria obtained from respiratory
secretions of lung cancer patients were characterized by
high in vitro susceptibility to applied antibiotics and che-
motherapeutics. The MIC values of antibacterial agents
and number of resistant strains are listed in Table 2.
Among the beta-lactam antibiotics used in the study,
Table 1. Anaerobic bacteria isolated from bronchial
secretions in lung cancer patients
Species Number (%) of isolates
Gram-positive
Actinomyces israelii 6 (12.77)
Actinomyces viscosus 5 (10.64)
Acrinomyces naeslundii 4 (8.51)
Peptostreptococcus spp. 14 (29.79)
Eubacterium lentum 7 (14.89)
Lactobacillus jensenii 1 (2.13)
Gram-negative
Veillonella parvula 6 (12.77)
Prevotella melaninogenica 1 (2.13)
Prevotella oralis 1 (2.13)
Prevotella spp. 1 (2.13)
Bacteroides spp. 1 (2.13)
Total 47 (100)
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the most in vitro active against these microorganisms
were amoxicillin/clavulanate and imipenem (0% and 2%
resistant strains, respectively), followed by cefoxitin (9%
resistant strains), and piperacillin/tazobactam (16% re-
sistant strains). 29% of isolates were resistant to penicil-
lin G. Among antimicrobial agents not belonging to beta-
-lactams, the highest resistance rate was observed with
metronidazole (38% resistant strains); 16% isolates were
resistant in cases of clindamycin.
Among the tested anaerobes, 10/47 (21.28%)
strains produced beta-lactamase as follows: Actino-
myces spp. (4/47 strains; 8.51%), Peptostreptococcus
spp. (3/47 strains; 6.38%), V. parvula (2/47 strains;
4.26%), Bacteroides spp. (1/47 strain; 2.13%).
Discussion
Pneumonia, including nosocomial pneumonia, is one
of the main complications occurring in lung cancer
patients due to defects in the clearance system in sites
peripheral to the bronchial obstruction, or stenosis
caused by cancer therapy as well as cancer itself and
broad-spectrum antibiotics usage [7–14]. The role of
anaerobes in the pathogenesis of pneumonia in hos-
pitalized patients, especially in critically or chronically
ill patients, is still controversial [4, 15, 16]. It is known
that pneumonia is preceded by microbial coloniza-
tion of the lower airways [17]. In our studies, heavy
colonization of lower airways by anaerobic bacteria,
mainly potentially pathogenic species, was found in
the lung cancer group, comprising 73.3% of the pa-
tients. Fiberoscopic bronchoscopy using a protected
specimen brush (PSB) catheter was applied as a highly
sensitive and specific technique to obtain uncontam-
inated specimens for anaerobic cultures from the low-
er respiratory tract. Among the isolated anaerobes
the clinically important Gram-positive bacteria were
classified, including cocci belonging to Peptostrepto-
coccus spp. and non-spore-forming bacilli, primarily
Actinomyces spp.
Several classes of antimicrobial agents have good
activity against anaerobic bacteria, including penicillins
alone or in combination with beta-lactamase inhibitors,
cephalosporins, carbapenems, chloramphenicol, clinda-
mycin, metronidazole, glycopeptides, macrolides, tetra-
cyclines or fluoroquinolones [2, 18, 19]. However, anti-
microbial resistance of anaerobes has become an increas-
ing problem over the past two decades; beta-lactamase
production is one of the commonest resistance mecha-
nisms [20, 21]. According to our data, the anaerobic
bacteria isolated from bronchial secretions in lung can-
cer patients were susceptible to the majority of the test-
ed antimicrobials. The strains producing beta-lactamase
comprise only about 20% of the isolates. Amoxicillin/
/clavulanate was the only antimicrobial agent active
against all the tested isolates, which may be important
in the choice of empiric therapy not only for anaerobic
but also for mixed infections. Moreover, among the test-
ed anaerobes, representing mainly Gram-positive bac-
teria, the lowest resistance rates were for imipenem and
cefoxitin, while the highest were for metronidazole and
penicillin G. Consistent with the results of previous stud-
ies [18, 20, 22], the rates of resistance may show clinical-
ly important variations among geographic areas and be-
tween countries.
In conclusion, the results presented in this paper
confirm the need to conduct analyses of microflora
colonizing the lower respiratory tract in lung cancer
patients, including anaerobic bacteria, to monitor
potential etiologic agents of airways infections.
Knowledge of the actual frequency of occurrence of
pathogenic, as well as opportunistic, species in a giv-
en local population is necessary in order to propose
efficient, empirical therapy for respiratory tract in-
fections, taking into account the possible involvement
of anaerobic bacteria.
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